Document Type : Research Articles
Authors
1
Pathology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
2
Gynecologic Oncology Unit, Department of Obstetrics and Gynecology, Women Health Hospital, Faculty of Medicine, Assiut University, Assiut, Egypt.
3
Clinical Oncology Department, Faculty of Medicine, Assiut University, Assiut, Egypt.
4
Department of Medical Oncology and Hematological Malignancy, South Egypt Cancer Institute, Assiut University, Assiut, Egypt.
5
House Officer at Assiut University Hospitals, Faculty of Medicine, Assiut University, Assiut, Egypt.
Abstract
Objectives: This study aims to investigate the clinicopathological significance and prognostic impact of SLFN11 expression and tumor-infiltrating lymphocytes (TILs) in high-grade and low-grade ovarian serous carcinoma. Methods: A total of 70 patients diagnosed with high-grade and low-grade serous carcinoma were retrospectively analyzed. Clinical data, including age, Karnofsky Performance Status (KPS), CA125 levels, treatment details, and survival outcomes, were collected. Immunohistochemistry was used to assess SLFN11 expression in tumor cells and TILs. Statistical correlations were performed with chemotherapy response, recurrence, progression-free survival (PFS), and overall survival (OS). Results: High SLFN11 expression was significantly associated with better response to neoadjuvant chemotherapy (p = 0.003), higher histopathologic chemotherapy response score (p = 0.026), lower recurrence rate (p = 0.037), and improved survival outcomes (p < 0.001). High SLFN11 expression had significantly longer PFS (median= 33.05 months) and OS (median= 66.91 months), compared to those with low SLFN11 expression (median PFS =7.60 and median OS = 31.50, p<0.001). Similarly, high TILs count was associated with improved response to neoadjuvant chemotherapy (p = 0.008) and higher response score (p = 0.007). TILs-high patients had longer median PFS (25.52 months) and median OS (68.24 months) than TILs-low patients (median PFS = 10.30 and median OS = 30.63 months, p<0.001). Conclusion: Our findings highlight that immunohistochemical expression of SLFN11 and the density of TILs may serve as predictive biomarkers for chemotherapy response and survival in ovarian serous carcinoma, with potential implications for personalized treatment strategies.
Keywords
Main Subjects
)